Cigna Group (CI) Looks 58% Undervalued, Is The Recent Pullback A Buying Opportunity?

Cigna Group (CI) has drawn fresh attention after recent share performance left the stock down 5% over the past month and 6% over the past 3 months. That price drift now sits alongside a sizeable health services operation.

Viewed over a longer stretch, Cigna Group has seen its share price drift, with the stock down over the year-to-date and the 1-year total shareholder return also declining. However, the 5-year total shareholder return remains positive and relatively strong.

Compare Cigna Group's recent pullback with hand picked health insurers and benefits providers that have been screened for resilient balance sheets and cash flows in our list of solid balance sheet and fundamentals (23 results).

Bulls see Cigna Group’s recent share pullback as a chance to buy a large health services player at a discount, while bears question whether the slide reflects deeper concerns. Which side does the current valuation support?

Most Popular Narrative: 58% Undervalued

Cigna Group last closed at $265.50, while the most followed valuation narrative pegs fair value near $636 per share, which paints a very different picture of what this pullback might represent.

Cigna trades 55% below what our model says it is worth. An insurer would never quote a policy from a number that seductive without reading the exclusions, inspecting the claims history, and asking what could go catastrophically wrong. So neither did we, and the file contains a fair, intelligent case for disagreeing with our verdict.

See why 3 investors see Cigna Group as 58% undervalued.

According to John_Eric, who authored the widely followed narrative on Cigna Group, the appeal rests on a large gap between current pricing and an internally assessed value, but the document also stresses that regulatory pressure, litigation around automated claims handling, customer contraction and questions around cash conversion all warrant a meaningful discount to any model output. The narrative effectively treats Cigna like an insurance policy, arguing that a raw valuation gap is not enough on its own and that investors need to decide how much uncertainty they are truly being paid to accept.

In that framework, the headline fair value of roughly $636 per share is adjusted by a conviction score that factors in both the perceived strength of Cigna’s Evernorth health services platform and the long list of open questions, which brings the effective margin of safety down to the mid 20% range rather than the raw headline gap. That approach is especially relevant for a large health insurer where political scrutiny of pharmacy benefit management models, rebate structures and automation in claims review can influence future earnings quality in ways that backward looking results do not fully capture.

Result: Fair Value of $636 (UNDERVALUED)

Still, the FTC settlement around Express Scripts and the unresolved PxDx algorithm lawsuit could shift how investors view Cigna Group’s cash generation and the economics of Evernorth.

Find out about the key risks to this Cigna Group narrative.

Next Steps

Mixed feelings after reading about Cigna Group's pullback and valuation gap are reasonable. It may be helpful to move quickly, review the full picture and weigh the 6 key rewards and 1 important warning sign.

Looking for more Cigna Group investment ideas?

If Cigna Group has you thinking harder about where to put fresh capital, consider broadening your watchlist with a few focused idea sets from the Simply Wall Street Screener.

• Target durable quality by reviewing companies with healthy finances in the list of solid balance sheet and fundamentals (23 results).
• Hunt for potential value gaps by scanning the 16 high quality undiscovered gems before they hit everyone's radar.
• Dial back portfolio risk by filtering for steadier profiles using the 31 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com